Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AML
Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.
Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo (AMP 2019), in which the patient with acute myeloid leukemia (AML) harboring aFLT3-TKD mutation lost the mutation following relapse on gilteritinib (Xospata).
The FLT3 tyrosine kinase inhibitor gilteritinib, which wasapproved by the FDA in November of 2018 for adult patients withFLT3-mutant AML, is efficacious in many different patients withFLT3-mutant AML, but the case of the patient losing the mutation upon relapse is unexpected. This kind of event has not been reported much in literature, and there is not a lot of discussion about the disappearance of aFLT3-TKD following relapse on a TKI, Fisch says.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
